Table 28: Clinical evidence profile: Antidepressants (fluoxetine) versus antipsychotics (amisulpride)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Antidepressants (fluoxetine) versus antipsychotics (amisulpride)	Control	Relative (95% CI)	Absolute		
Quality of Life: SF12 (follow-up 12 weeks; range of scores: 0-100; Better indicated by higher values)												
1	randomised trials	very serious[1]	no serious inconsistency	serious[2]	no serious imprecision	none	20	20	-	MD 15.6 lower (18.61 to 12.59 lower)	⊕OOO VERY LOW	CRITICAL
Fatigue: Fatigue Severity Scale (follow-up 12 weeks; range of scores: 9-63; Better indicated by lower values)												

1	randomised trials	very serious[1]	no serious inconsistency	serious[2]	no serious imprecision	none	20	20	-	MD 12.6 higher (8.26 to 16.94 higher)	⊕OOO VERY LOW	CRITICAL
Psychological status: HADS anxiety (follow-up 12 weeks; range of scores: 0-21; Better indicated by lower values)												
1	randomised trials	very serious[1]	no serious inconsistency	serious[2]	serious[3]	none	20	20	-	MD 0.4 higher (0.22 lower to 1.02 higher)	⊕OOO VERY LOW	CRITICAL
Psychological status: HADS depression (follow-up 12 weeks; range of scores: 0-21; Better indicated by lower values)												
1	randomised trials	very serious[1]	no serious inconsistency	serious[2]	serious[3]	none	20	20	-	MD 0.1 lower (0.69 lower to 0.49 higher)	⊕OOO VERY LOW	CRITICAL
Pain: pain on VAS (follow-up 12 weeks; range of scores: 0-100; Better indicated by lower values)												
1	randomised trials	very serious[1]	no serious inconsistency	serious[2]	no serious imprecision	none	20	20	-	MD 12.6 higher (5.8 to 19.4 higher)	⊕OOO VERY LOW	CRITICAL
Adverse events: FIBSER global burden (follow-up 12 weeks; range of scores: not reported; Better indicated by lower values)												
1	randomised trials	very serious[1]	no serious inconsistency	serious[2]	serious[3]	none	20	20	-	MD 0.2 lower (0.67 lower to 0.27 higher)	⊕OOO VERY LOW	CRITICAL
Symptom scales: Clinical Global Impression Severity (CGI-S) (follow-up 12 weeks; range of scores: 1-7; Better indicated by lower values)												
1	randomised trials	very serious[1]	no serious inconsistency	serious[2]	no serious imprecision	none	20	20	-	MD 1.3 higher (0.75 to 1.85 higher)	⊕OOO VERY LOW	CRITICAL

[1] Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
[2] The majority of the evidence included an indirect population (downgraded by one increment) or a very indirect population (downgraded by two increments). Populations were downgraded if the ME/CFS diagnostic criteria used did not include PEM as a compulsory feature
[3] Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs